Yunnan Baiyao Group Co Ltd
SZSE:000538
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Yunnan Baiyao Group Co Ltd
Other Current Liabilities
Yunnan Baiyao Group Co Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Current Liabilities
¥3.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
10%
|
|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Other Current Liabilities
¥7.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Current Liabilities
¥4B
|
CAGR 3-Years
106%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Current Liabilities
¥3.9B
|
CAGR 3-Years
82%
|
CAGR 5-Years
11%
|
CAGR 10-Years
24%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Other Current Liabilities
¥919.3m
|
CAGR 3-Years
52%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Current Liabilities
¥435.5m
|
CAGR 3-Years
74%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
Yunnan Baiyao Group Co Ltd
Glance View
Yunnan Baiyao Group Co Ltd is a captivating story of fusion between traditional Chinese medicine and modern business acumen. Rooted in Yunnan province's rich heritage, the company traces its origins back to the early 1900s when a local healer discovered a potent remedy for addressing wounds and reducing bleeding. Over the years, this original formula, a tightly-kept secret, evolved into a cornerstone product that propelled Yunnan Baiyao into the spotlight. As the company expanded, it embraced an adept strategy of integrating traditional formulations with contemporary pharmaceutical practices, enabling it to carve out a niche within the global health sector. Today, Yunnan Baiyao Group boasts a diversified portfolio that extends beyond its flagship product to include various health care, personal care, and even veterinary offerings. Its revenue model intricately weaves together streams from over-the-counter remedies, prescription medications, and consumer healthcare products. The company's innovative stride into the realms of cosmetics and toothpaste indicates its agility in adapting ancient knowledge for contemporary consumer demands. Strategic marketing emphasizes the unique heritage and trusted efficacy of its products, helping Yunnan Baiyao solidify its standing in a competitive market. As it continues to grow, the group remains a compelling example of how deeply-rooted tradition can be harnessed to drive a modern enterprise to sustained profitability.
See Also
What is Yunnan Baiyao Group Co Ltd's Other Current Liabilities?
Other Current Liabilities
3.1B
CNY
Based on the financial report for Dec 31, 2025, Yunnan Baiyao Group Co Ltd's Other Current Liabilities amounts to 3.1B CNY.
What is Yunnan Baiyao Group Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
10%
Over the last year, the Other Current Liabilities growth was -15%. The average annual Other Current Liabilities growth rates for Yunnan Baiyao Group Co Ltd have been -11% over the past three years , -11% over the past five years , and 10% over the past ten years .